Luseogliflozin

Luseogliflozin is a pharmaceutical drug used for the treatment of type 2 diabetes mellitus. It was approved for use in Japan in 2014.
In a meta-analysis involving data from 10 randomized controlled trials, Dutta et. al. demonstrated the good glycaemic efficacy and safety of luseogliflozin 2.5mg/day as compared to placebo. Additional benefits include significant reduction in systolic blood pressure, serum triglycerides, uric acid and alanine aminotransferase as compared to placebo, highlighting the beneficial impact on the different aspects of metabolic syndrome.